Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Founded in 1988, Regeneron's first major success was Eylea, a breakthrough Anti-VEGF therapy for previously untreatable eye condition Wet-AMD.

Regeneron: All-Time High Share Price Hasn't Yet Reached Full Potential

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: Regeneron

Trade Desk

Wood might regret trimming her positions in these great growth stocks.

3 Growth Stocks Cathie Wood Is Selling That Are Still Worth Buying

The biotech's EUA expansion for REGEN-COV will probably provide only an incremental sales boost.

Regeneron's Antibody Cocktail Authorized for Preventing COVID: Why It's Not a Big Deal for the Stock

Is (REGN) Outperforming Other Medical Stocks This Year?

Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received a price target increase from $725 to $825 by Oppenheimer. These are the details.

REGN Stock Price: $825 Target From Oppenheimer

Ocular Therapeutix

Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

Regeneron Pharmaceuticals Inc. (REGN) CEO Leonard Schleifer on Q2 2021 Results - Earnings Call Transcript

Regeneron (REGN) beats on Q2 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and significant contribution from REGEN-COV.

Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance

Sanofi

The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC).  These data are planned to form the basis of regulatory submissions in the U.S. and European Union.

Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $25.80 per share for the second quarter, beating the $17.69 estimate.  It clocked revenue of $5.1 billion, surpassing the analysts' consensus of $3.89 billion and higher than $1.95 billion a year ago, primarily attributable to sales from COVID-19 treatment, REGEN-COV.

Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend Outlook

Regeneron (REGN) delivered earnings and revenue surprises of 31.97% and 31.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Q2 Earnings and Revenues Top Estimates

The company credited record sales of asthma medication Dupixent and age-related macular degeneration drug Eylea, among other factors, for the beat.

Regeneron Earnings Top Estimates. Its Stock May Be Breaking Out.

Regeneron Pharmaceuticals Inc. shares jumped 3.3% in premarket trade Thursday, after . Tarrytown, New York-based Regeneron posted net income of $$3.099 billion, or $27.97 a share, for the quarter, up from $897 million, or $7.61 a share, in the year-earlier period.

Regeneron shares jump 3.3% premarket after earnings blow past estimates; COVID antibody sales total $2.59 billion

Regeneron Pharmaceuticals Inc reported a more than tripling of its quarterly profit on Thursday, buoyed by robust demand for its COVID-19 antibody cocktail.

Regeneron quarterly profit surges on COVID-19 antibody cocktail demand

TARRYTOWN, N.Y., Aug. 5, 2021 /PRNewswire/ --   Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COV TM(2) ; revenues excluding REGEN-COV (1)(2) increased 22% Second quarter 2021 EYLEA® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billion Second quarter 2021 Dupixent® global net sales (3) , which are recorded by Sanofi, increased 59% to $1.50 billion versus second quarter 2020 Second quarter 2021 GAAP diluted EPS was $27.97 and non-GAAP diluted EPS (1) was $25.80 FDA updated REGEN-COV Emergency Use Authorization (EUA) with lower dose, subcutaneous administration, and post-exposure prophylaxis REGEN-COV Phase 3 RECOVERY trial in hospitalized patients with severe COVID-19 met primary outcome Reported that Dupixent significantly improved itch and hives in patients with chronic spontaneous urticaria, marking the fifth disease to show positive pivotal results Phase 3 trial of Libtayo® combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2021 and provided a business update.

Regeneron Reports Second Quarter 2021 Financial and Operating Results

Gilead Sciences

Moderna

All three have blockbuster products already on the market.

3 Biotech Stocks That Could Make You Richer in August (and Beyond)

Phase 3 t rial of Libtayo ® ( cemiplimab ) c ombined with c hemotherapy s topped e arly d ue to s ignificant i mprovement in o verall s urvival in p atients with f irst-line a dvanced n on-small c ell l ung c ancer

Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

TARRYTOWN, N.Y. and PARIS, Aug. 5, 2021 /PRNewswire/ -- Libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death Trial enrolled patients with locally advanced and metastatic disease with squamous or non-squamous histology, across all PD-L1 expression levels Libtayo has now demonstrated improved overall survival as a monotherapy or in combination with chemotherapy in first-line advanced non-small cell lung cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the Phase 3 trial of PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small cell lung cancer (NSCLC).

Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer

TARRYTOWN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals.

New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection

Illumina

Johnson & Johnson

Novartis

Zoetis

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

TARRYTOWN, N.Y., Aug. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced winners of the ninth annual Regeneron Prize for Creative Innovation, a competition designed to recognize creativity and independent scientific thinking among postdoctoral fellows and graduate students focused on biomedical research.

Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation

Regeneron has developed some truly life changing treatment options and has exposure to some undertreated spaces. The stock has run up quite a bit on their stellar performances in the past.

Regeneron: Rapid Growth Seems To Be On A Pause

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?

Roche Holding AG

Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the investigational COVID-19 antibody cocktail. REGEN-COV (casirivimab and imdevimab) has been developed by Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche Holdings AG (OTC:RHHBY).

News for Regeneron Pharmaceuticals Stock (REGN)